Sir,

Pyridoxine-dependent epilepsy (PDE) is an inborn error of lysine metabolism characterized by neonatal-onset refractory seizures that are responsive to pharmacologic doses of pyridoxine. Majority of cases are associated with variations in the antiquitin gene \( \text{ALDH7A1} \), which encodes for alpha-amino-adipic semialdehyde dehydrogenase enzyme. The deficiency of this enzyme results in accumulation of metabolites such as alpha-aminoacidic semialdehyde and piperidine-6-carboxylate, which inactivate pyridoxal phosphate (the active form of pyridoxine) and cause pyridoxine dependency.\(^{[1]} \) The disorder has a prevalence of 1 in 100,000–700,000 individuals.\(^{[2-3]} \)

PDE has been associated with several structural brain abnormalities, although none of these is pathognomonic for the disorder.\(^{[4,5]} \) In a review of brain malformations associated with PDE, agenesis/hypoplasia of corpus callosum (33%), nonspecific white matter abnormalities (32%), mega cisterna magna (17%), ventriculomegaly (17%), hemorrhages (15%), cerebellar hypoplasia/dysplasia (12%), cortical atrophy (8%), hydrocephalus (8%), dysplasia of corpus callosum (7%), and cysts (5%) have been noted.\(^{[6]} \) We discuss here a young boy with PDE who developed acute hydrocephalus during an episode of breakthrough status epilepticus. Our case highlights the need to recognize the association of PDE with hydrocephalus to guide appropriate management. Additionally, the presence of hydrocephalus in children with refractory epilepsy should guide investigations to exclude an underlying PDE, especially in cases with early-onset treatment refractory epilepsies.

A 13-month-old infant with epilepsy and language delay presented with unprovoked, focal-onset left-sided motor seizures for 1 day, followed by a generalized status epilepticus. There was no preceding history of fever, alteration in sensorium, missed or changed dosing schedule, trauma, or intercurrent illness. The infant was fourth in birth order; the parents were nonconsanguineously married and there was no family history of epilepsy. He had been delivered by cesarean section for fetal distress. On examination during his deterioration at 13 months of age, he had normal head circumference (45.5 cm; 0 to −3 Z-core), encephalopathy with generalized hypotonia, normal muscle stretch reflexes, and bilateral Babinski’s sign. Rest of the systemic examination was unremarkable. A computed tomography scan of the head showed diffuse cerebral edema. He required mechanical ventilation, omsotherapy (3% hypertonic saline) for raised intracranial pressure, anticonvulsants for control of status epilepticus (including folinic acid, phenytoin, levetiracetam, lacosamide) and intravenous antimicrobials. He developed hepatitis, hemolysis, rhabdomyolysis, renal dysfunction, and myocardial dysfunction attributed to prolonged status epilepticus. After control of seizures, he developed generalized, severe dystonia and was continued on supportive measures. He was discharged after 3 weeks of hospital stay in a vegetative state with tracheostomy-tube \textit{in-situ}, nasogastric feeding, anticonvulsant (levetiracetam 40 mg/kg/day, phenytoin 6 mg/kg/day, lacosamide 10 mg/kg/day), and antidystonia and antispasticity drugs (baclofen 30 mg/day, trihexyphenidyl 12 mg/day, diazepam 2 mg/kg/day, clonidine 0.5 mcg/kg/day), in addition to 500 mg/day oral pyridoxine and 3 mg/kg/day folinic acid. MRI of the brain after discharge showed arrested hydrocephalus [Figure 2]. Currently, at 1 year of follow-up, he is in a chronic vegetative state, with a head circumference of 47 cm (−1 to −2 Z-score) with control of further seizures.

Our case illustrates the unusual association of acute hydrocephalus with PDE. Additionally, our cases also highlights the natural course of PDE in infants and children who may remain seizure-free for several years and may show worsening of epilepsy with acute neurological deterioration and poor neurodevelopmental outcomes, despite timely diagnosis and regular pyridoxine supplementation.

The disorder has a prevalence of 1 in 100,000–700,000 individuals. The diagnosis of PDE was assigned. Electroencephalogram showed epileptic encephalopathy and normalized after pyridoxine supplementation. Magnetic resonance imaging (MRI) of the brain showed markedly thinned-out corpus callosum with colpocephaly [Figure 1]. He was discharged by the end of the first week of life and remained seizure-free on oral pyridoxine supplementation. The other anticonvulsants were gradually tapered and stopped on follow-up. Next generation sequencing of the \( \text{ALDH7A1} \) gene showed a homozygous pathogenic variant (c. 1115delT) in exon 13 resulting in a frameshift and premature truncation of the protein, which was predicted to be damaging by \textit{in-silico} prediction models. Sanger sequencing confirmed the variant, but parental testing was denied by the family. In follow-up, he had speech delay without other autistic features, with age-appropriate motor and cognitive milestones.

On examination during his deterioration at 13 months of age, he had normal head circumference (45.5 cm; 0 to −3 Z-core), encephalopathy with generalized hypotonia, normal muscle stretch reflexes, and bilateral Babinski’s sign. Rest of the systemic examination was unremarkable. A computed tomography scan of the head showed diffuse cerebral edema. He required mechanical ventilation, omsotherapy (3% hypertonic saline) for raised intracranial pressure, anticonvulsants for control of status epilepticus (including folinic acid, phenytoin, levetiracetam, lacosamide) and intravenous antimicrobials. He developed hepatitis, hemolysis, rhabdomyolysis, renal dysfunction, and myocardial dysfunction attributed to prolonged status epilepticus. After control of seizures, he developed generalized, severe dystonia and was continued on supportive measures. He was discharged after 3 weeks of hospital stay in a vegetative state with tracheostomy-tube \textit{in-situ}, nasogastric feeding, anticonvulsant (levetiracetam 40 mg/kg/day, phenytoin 6 mg/kg/day, lacosamide 10 mg/kg/day), and antidystonia and antispasticity drugs (baclofen 30 mg/day, trihexyphenidyl 12 mg/day, diazepam 2 mg/kg/day, clonidine 0.5 mcg/kg/day), in addition to 500 mg/day oral pyridoxine and 3 mg/kg/day folinic acid. MRI of the brain after discharge showed arrested hydrocephalus [Figure 2]. Currently, at 1 year of follow-up, he is in a chronic vegetative state, with a head circumference of 47 cm (−1 to −2 Z-score) with control of further seizures.

Our case illustrates the unusual association of acute hydrocephalus with PDE. Additionally, our cases also highlights the natural course of PDE in infants and children who may remain seizure-free for several years and may show worsening of epilepsy with acute neurological deterioration and poor neurodevelopmental outcomes, despite timely diagnosis and regular pyridoxine supplementation.
in their series of patients, of which the majority developed hydrocephalus as a later complication and only a few infants were diagnosed with antenatal ventriculomegaly. In one of our previous patients with neonatal-onset PDE, obstructive hydrocephalus was noted in follow-up. Various hypotheses have been formulated to explain this phenomenon. It has been postulated that recurrent neonatal intracerebral micro-hemorrhages, which occur in patients with PDE (unclear mechanism) could lead to gliotic changes causing aqueductal stenosis and subsequent hydrocephalus. Also, the expression of antiquitin in the choroid plexus and ependymal cells, in addition to neuroglia, is thought to be involved in alteration of the CSF circulation, causing ventriculomegaly and/or symptomatic hydrocephalus. An additional contribution of severe hypoxia, secondary to prolonged status epilepticus, to gliosis in the cerebrospinal fluid pathways and subsequent hydrocephalus in our patient remains conjectural.

Although therapeutic doses of pyridoxine initiated and maintained in the early infantile period, result in excellent control of seizures, nearly two-thirds of patients may have intermittent breakthrough seizures and persistent neurocognitive abnormalities. The cause of breakthrough seizures remains unclear. The accumulation of substrates from lysine degradation, which is not reversed by pyridoxine therapy, and intercurrent febrile illnesses, which may increase the requirement of pyridoxine may be contributory. Short-term increase in the doses of pyridoxine and addition of folic acid have been recommended to treat breakthrough seizures in these patients. The long-term effects of the accumulating compounds including alpha-aminoadipic semialdehyde and piperidine-6-carboxylate, which is not corrected by pyridoxine alone, has also been postulated as the mechanism underlying the high rate of cognitive impairment. Hence, lysine-restriction and arginine supplementation as means of substrate reduction may be attempted to improve cognitive outcomes.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

Shivan Kesavan, Bhanudeep Singanamalla, Dangudubiyam Sri Krishna Sahitya, Arushi Gahlot Saini, Sameer Vyas

Departments of Pediatrics and Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India

**Address for correspondence:** Dr. Arushi Gahlot Saini, Department of Pediatrics, Pediatric Neurology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India. E-mail: doc.arushi@gmail.com

**REFERENCES**

1. van Karnebeek CDM, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, Coughlin CR, *et al.* Pyridoxine-dependent epilepsy: An expanding clinical spectrum. Pediatr Neurol 2016;59:6-12.
2. Baxter P. Epidemiology of pyridoxine dependent and pyridoxine-responsive seizures in the UK. Arch Dis Child 1999;81:431-3.
3. Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures.
4. Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010;133:2148-59.
5. Schmitt B, Baumgartner M, Mills PB, Clayton PT, Jakobs C, Keller E, et al. Seizures and paroxysmal events: Symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol 2010;52:e133-42.
6. Toldo I, Bonardi CM, Bettella E, Polli R, Talenti G, Burlina A, et al. Brain malformations associated to Aldh7a1 gene mutations: Report of a novel homozygous mutation and literature review. Eur J Paediatr Neurol 2018;22:1042-53.
7. Jansen LA, Hevner RF, Roden WH, Hahn SH, Jung S, Gospe SM. Glial localization of antiquitin: Implications for pyridoxine-dependent epilepsy. Ann Neurol 2014;75:22-32.
8. Navarro-Abia V, Soriano-Ramos M, Núñez-Enamorado N, Camacho-Salas A, Martínez-de Aragón A, Martín-Hernández E, et al. Hydrocephalus in pyridoxine-dependent epilepsy: New case and literature review. Brain Dev 2018;40:348-52.
9. Suthar R, Saini SS, Sahu JK, Singhi P. Obstructive hydrocephalus in pyridoxine-dependent epilepsy: An uncommon complication. Pediatr Neurol 2017;69:e1-2.
10. Stockler S, Plecko B, Gospe SM, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: Clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011;104:48-60.